Table 1.

Main inclusion and exclusion criteria of the CONSUL study

Inclusion criteria	Exclusion criteria
Age ≥18 years	Presence of total spinal ankylosis
Definite diagnosis of AS according to the modified New York criteria	History of primary non-response to previous anti-TNF therapy (if any)
Active disease (defined as BASDAI≥4)	Contraindications for the treatment with golimumab and/or celecoxib
History of an inadequate response to a therapeutic trials of at least two NSAIDs
Risk factors for radiographic spinal progression (defined as elevated CRP or existing syndesmophytes) at screening

AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; NSAIDs, non-steroidal anti- inflammatory drugs; TNF, tumour necrosis factor.